Education
About Us
Working with TipRanks
Follow Us
Damora Therapeutics (DMRA)
NASDAQ:DMRA
| Dec 24 | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 0.00 | $ 0.00 | $ 0.00 | $ 0.00 | $ 0.00 |
| Gross Profit | $ -181.00K | $ -830.00K | $ -490.00K | $ -441.00K | $ -188.00K |
| Operating Income | $ -16.90M | $ -36.46M | $ -61.21M | $ -52.23M | $ -33.64M |
| EBITDA | $ -16.72M | $ -35.63M | $ -60.72M | $ -51.79M | $ -33.45M |
| Net Income | $ -21.44M | $ -38.35M | $ -61.62M | $ -51.75M | $ -34.84M |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 14.18M | $ 33.15M | $ 60.22M | $ 100.19M | $ 163.58M |
| Total Assets | $ 17.13M | $ 38.23M | $ 73.19M | $ 122.22M | $ 171.60M |
| Total Debt | $ 1.43M | $ 249.00K | $ 804.00K | $ 847.00K | $ 915.00K |
| Net Debt | $ -12.74M | $ -21.22M | $ -31.98M | $ -61.72M | $ -162.67M |
| Total Liabilities | $ 2.66M | $ 5.90M | $ 11.44M | $ 4.99M | $ 6.11M |
| Stockholders' Equity | $ 14.47M | $ 32.33M | $ 61.75M | $ 117.22M | $ 165.49M |
| Cash Flow | |||||
| Free Cash Flow | $ -18.62M | $ -36.91M | $ -43.13M | $ -52.53M | $ -38.20M |
| Operating Cash Flow | $ -18.62M | $ -36.91M | $ -42.93M | $ -52.31M | $ -38.20M |
| Investing Cash Flow | $ 11.65M | $ 22.33M | $ 12.38M | $ -48.05M | $ 0.00 |
| Financing Cash Flow | $ 0.00 | $ 2.88M | $ 507.00K | $ 0.00 | $ 187.39M |
Damora Therapeutics Forecast EPS vs Actual EPS
Currently, no data available
Please return soon. This page is being updated.